Stephen J. Schuster, MD, University of Pennsylvania School of Medicine, Philadelphia, Pa., speaking at ASCO 2009: Therapeutic Cancer Vaccine Significantly Prolongs Disease-Free Survival for Follicular Lymphoma: An eight-year randomized, controlled phase III clinical study has shown that a patient-specific therapeutic vaccine, BiovaxID, significantly prolongs disease-free survival in follicular non-Hodgkin’s lymphoma. The study, which is being featured in ASCO’s plenary session, found that patients who received the vaccine experienced a median disease-free survival of approximately 44 months compared to approximately 30 months for those who received a control vaccine – an increase of 47 percent.